



Department of Health and Human Services  
MaineCare Services  
11 State House Station  
Augusta, Maine 04333-0011  
Tel.: (207) 287-2674; Fax: (207) 287-2675  
TTY Users: Dial 711 (Maine Relay)

## DUR COMMITTEE AGENDA

Date: Tuesday, September 13, 2016  
Time: 5:30PM to 8:30PM  
Location: Augusta Armory, 179 Western Avenue, Augusta, ME

- 1) Call to Order
- 2) Introductions of New Committee Members
- 3) MaineCare Updates
- 4) Public Comments
- 5) Old Business
  - Review of Minutes
- 6) Closed Session
  - Drug Financial Information Review
- 7) New Business (open session)
  - A. Retro-DUR Schedule 2017
  - B. Retro-DUR
    - Present Results - Diabetes – appropriate utilization of angiotensin modulators in patients with diabetes and hypertension
  - C. New Drug Review
    - Bevespi
    - Briviact
    - Epclusa
    - Keveyis
    - Kyprolis
    - Nuplazid
    - Ocaliva
    - Tecentriq
    - Viekira XR
    - Xiidra
    - Xtampza ER
    - Zinbryta
  - D. FDA Safety Alerts
    - Multistate Outbreak of Burkholderia cepacia Infections

[http://www.cdc.gov/hai/outbreaks/b-cepacia/index.html?source=govdelivery&utm\\_medium=email&utm\\_source=govdelivery](http://www.cdc.gov/hai/outbreaks/b-cepacia/index.html?source=govdelivery&utm_medium=email&utm_source=govdelivery)

- Zecuity (sumatriptan) Migraine Patch: Drug Safety Communication - FDA Evaluating Risk of Burns and Scars  
[http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm504736.htm?source=govdelivery&utm\\_medium=email&utm\\_source=govdelivery](http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm504736.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery)
- FDA Drug Safety Communication: FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium), including from abuse and misuse  
[http://www.fda.gov/Drugs/DrugSafety/ucm504617.htm?source=govdelivery&utm\\_medium=email&utm\\_source=govdelivery](http://www.fda.gov/Drugs/DrugSafety/ucm504617.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery)
- FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR)  
[http://www.fda.gov/Drugs/DrugSafety/ucm505860.htm?source=govdelivery&utm\\_medium=email&utm\\_source=govdelivery](http://www.fda.gov/Drugs/DrugSafety/ucm505860.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery)
- FDA Drug Safety Communication: FDA warns about serious bleeding risk with over-the-counter antacid products containing aspirin  
[http://www.fda.gov/Drugs/DrugSafety/ucm504328.htm?source=govdelivery&utm\\_medium=email&utm\\_source=govdelivery](http://www.fda.gov/Drugs/DrugSafety/ucm504328.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery)
- FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects  
[http://www.fda.gov/Drugs/DrugSafety/ucm511530.htm?source=govdelivery&utm\\_medium=email&utm\\_source=govdelivery](http://www.fda.gov/Drugs/DrugSafety/ucm511530.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery)

E. Next Meeting (Tuesday, October 11, 2016 from 12pm to 4pm)

F. Adjournment: 8:30PM